CLAIMS

1. Use of a lactic acid bacterial product by lactic acid bacteria of the genus *Lactobacillus* in the manufacture of a composition for suppressing deterioration of an acquired immune function due to the use of an anti-influenza drug.

2. The use according to claim 1, wherein the lactic acid bacteria of the genus *Lactobacillus* is classified as a subspecies *bulgaricus*.

3. The use according to claim 1 or 2, wherein the lactic acid bacteria of the genus *Lactobacillus* is *Lactobacillus delbrueckii* subsp. *bulgaricus*.

4. The use according to any one of claims 1 to 3, wherein the lactic acid bacterial product is selected from lactic acid bacteria fermented products, lactic acid bacteria cultures, and lactic acid bacteria metabolites.

5. The use according to any one of claims 1 to 4, wherein the lactic acid bacterial product is lactic acid bacteria milk fermented product or lactic acid bacteria milk culture.

6. The use according to any one of claims 1 to 5, wherein the lactic acid bacterial product contains extracellular polysaccharide (EPS).

7. Use of a lactic acid bacterial product by lactic acid bacteria of the genus *Lactobacillus* in the manufacture of a composition for preventing a decrease in the production amount of the antibody specific to influenza virus produced in vivo.

8. A method for producing a composition for suppressing deterioration of an acquired immune function for supplying a milk raw material to a lactic acid bacterium of the genus *Lactobacillus* and suppressing deterioration of the acquired immune function due to the use of an anti-influenza drug.

9. The method according to claim 8, wherein the composition further has an infection inhibitory action against influenza virus.